2. Anti-infection
  3. Bacterial
  4. Bezlotoxumab

Bezlotoxumab  (Synonyms: BLA761046; MBL-CDB1; MDX-1388)

Art. -Nr.: HY-P9929 Reinheit: 97.00%
COA
SDS
Technical Support

Bezlotoxumab (BLA761046; MBL-CDB1; MDX-1388) is a fully humanized IgG1/kappa monoclonal antibody directed against Clostridium difficile toxin B. Bezlotoxumab mediates the early reconstitution of gut microbiota to reduce the risk of recurrent Clostridium difficile infection (CDI). Bezlotoxumab can be used for the study of recurrent Clostridium difficile infection prevention.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

CAS. Nr. : 1246264-45-8

Größe Preis Verfügbarkeit Menge
1 mg Auf Lager
5 mg Auf Lager
10 mg Auf Lager
50 mg   Angebot einholen  
100 mg   Angebot einholen  

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

This product is a controlled substance and not for sale in your territory.

Kundenbewertung

Based on 1 publication(s) in Google Scholar

Bezlotoxumab Spezialitätsempfehlungen:

Bezlotoxumab Related Antibodies

Top Publications Citing Use of Products

1 Publications Citing Use of MCE Bezlotoxumab

  • Biologische Aktivität

  • Reinheit & Dokumentation

  • Verweise

  • Kundenbewertung

Beschreibung

Bezlotoxumab (BLA761046; MBL-CDB1; MDX-1388) is a fully humanized IgG1/kappa monoclonal antibody directed against Clostridium difficile toxin B. Bezlotoxumab mediates the early reconstitution of gut microbiota to reduce the risk of recurrent Clostridium difficile infection (CDI). Bezlotoxumab can be used for the study of recurrent Clostridium difficile infection prevention[1][2][3].

Isotype

Human IgG1 kappa
Recommend Isotype Controls
Species Reactivity

Human
IC50 & Target

toxin B
In Vitro

Bezlotoxumab (100 μg/mL, 18 h pre-treatment) neutralizes TcdB-induced TER reduction in Caco-2 and MOCK cell monolayers[1].
Bezlotoxumab (100 μg/mL, 18 h pre-treatment) shows increased transport to the apical chamber of Caco-2 cells with rising TcdB concentration[1].
Bezlotoxumab (100 μg/mL, 18 h pre-treatment) inhibits TcdB-induced TER decrease in T84 cell monolayers, with Fc-independent neutralizing effects[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Bezlotoxumab Related Antibodies
In Vivo

Bezlotoxumab (250 μg/mouse, i.p., 1 day pre-infection) improves survival of both WT and FcRn-/- C57BL/6 mice in primary CDI model, combined with Actoxumab (HY-P99277)[1].
Bezlotoxumab (50 mg/kg, s.c., q.d. for 4 days) enhances survival and reduces symptoms in 100 g male Syrian hamsters with CDI combined with Actoxumab[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: 8-week-old female C57BL/6 wild-type or FcRn knockout mice[1]
Dosage: 250 μg/mouse
Administration: i.p., 1 day pre-infection
Result: Improved the survival rate of both wild-type and FcRn knockout mice.
Reduced the recurrence of CDI.
Animal Model: 100 g male Syrian hamsters[1]
Dosage: 50 mg/kg
Administration: s.c., q.d. for 4 days
Result: Improved the survival rate.
Klinische Studie
Gene ID

4914070  [NCBI]

Accession
Application

ELISA, FACS, Functional assay
Conjugated

Unconjugated
Reconsititution

The product can be reconstituted/diluted with sterile PBS or saline.
Molekulargewicht

145.54 kDa

CAS. Nr.
Appearance

Liquid

Color

Colorless to light yellow

SMILES

[Bezlotoxumab]
Formulation

Please refer to the lot-specific COA for specific buffer information.
Speicherung

Please store the product under the recommended conditions in the Certificate of Analysis.
Format
  • Human IgG1 kappa
Reinheit & Dokumentation
Verweise
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Bezlotoxumab Related Classifications

  • Molaritätsrechner

  • Verdünnungsrechner

Die Formel zur Berechnung von Molaritäten

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)

Diese Gleichung wird häufig abgekürzt als: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Bezlotoxumab1246264-45-8BLA761046 MBL-CDB1 MDX-1388BLA 761046BLA-761046MDX1388MDX 1388MDX-1388BacterialC. difficiletoxins Btoxins Aintestinal epithelialcolitisInhibitorinhibitorinhibit

Ihre kürzlich angesehenen Produkte:

Online-Anfrage

Your information is safe with us. * Required Fields.

Produktname

  

Requested Quantity *

Name des Antragstellers *

 

Anrede

E-Mail-Addresse *

 

Telefonnummer *

Department

 

Name der Organisation *

City

Bundesland

Country or Region *

      

Bemerkungen

Massenanfrage

Inquiry Information

Produktname:
Bezlotoxumab
Art. -Nr.:
HY-P9929
Menge:
MCE Japan Authorized Agent:

Kundenbewertung

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Produktname

  

Lot #

Name des Antragstellers *

 

E-Mail-Addresse *

Telefonnummer

 

Department *

Name der Organisation *

 

Country or Region *

Bemerkungen

SAFETY DATA SHEET (SDS)

English - EN (252 KB) Français - FR (252 KB) Deutsch - DE (252 KB) Norwegian - NO (252 KB) Español - ES (252 KB) Swedish - SV (252 KB) Italian - IT (252 KB) Korean - KR (252 KB) Portuguese - PT (252 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.